Oxford Biomedica PLC Board Change (8066H)
15 March 2018 - 6:02PM
UK Regulatory
TIDMOXB
RNS Number : 8066H
Oxford Biomedica PLC
15 March 2018
Board Change: Oxford BioMedica Appoints Heather Preston as
Non-Executive Director
London, UK - 15 March 2018: Oxford BioMedica plc ("Oxford
BioMedica" or "the Group") (LSE:OXB), a leading gene and cell
therapy group, today announces the appointment of Dr. Heather
Preston M.B.B Chir to the Group's Board as Non-Executive Director
with immediate effect.
Dr. Preston is currently a Partner and Managing Director of TPG
Biotech where she focuses on biotechnology venture capital
investing. Prior to joining TPG Biotech in May 2005, she invested
with J.P. Morgan Partners and New Enterprise Associates. She also
spent five years at McKinsey & Co. in New York, where she was a
member of the pharmaceutical and medical products consulting
practice. She advised large pharmaceutical and biotechnology
companies on critical strategic issues such as R&D portfolio
prioritisation, M&A opportunities, new technology acquisitions,
new product launches and product growth strategies.
Dr. Preston currently serves on the Board of Directors of
Albireo, Inc (NASDAQ; ALBO), Alder BioPharmaceuticals (NASDAQ;
ALDR) and Otonomy, Inc (NASDAQ; OTIC) and several private
companies. She previously served on the Boards of Aptalis Pharma
(acquired by Forest Labs in 2014), Elevation Pharmaceuticals
(acquired by Sunovion in 2012) and was responsible for overseeing
TPG Biotech's investment in Par Pharmaceuticals, prior to its
acquisition by Endo Pharmaceuticals in 2015.
Dr. Preston has an undergraduate degree in Biochemistry from the
University of London and a medical degree from the University of
Oxford. Dr Preston completed a post-doctoral fellowship in
Molecular Biology at the Dana Farber Cancer Institute, Harvard
University, and trained in Internal Medicine at the Massachusetts
General Hospital and sub-specialized in Gastroenterology and
Hepatology at UCSF. During her academic medical career, she was the
recipient of a Fulbright Scholarship, a Fulbright Cancer Research
Scholarship, a Harlech Scholarship and a Science and Engineering
Research Council Post-doctoral Fellowship Award.
Commenting on the announcement, Lorenzo Tallarigo, Chairman of
Oxford BioMedica, said: "I am delighted to welcome Heather to the
Board of Oxford BioMedica. Heather has a proven track record of
helping to grow life sciences companies in the US and Europe; as an
advisor, investor and Board member. Her industry knowledge is
directly aligned with Oxford BioMedica's strategy to take advantage
of our leading position with lentiviral vectors, both with our
partners and through our own in-house expertise."
Commenting on her appointment, Dr. Heather Preston, said:
"Oxford BioMedica's LentiVector Enabled technology makes the Group
a leader in the delivery of gene and cell therapies. This has been
clinically and commercially validated by partners including
Novartis, Sanofi, Orchard Therapeutics and, most recently
Bioverativ. I am excited by the prospects for the Group which is at
the forefront of what is a gene and cell therapy revolution, and I
look forward to working with the team."
On joining the Board Dr Preston will become a member of the
Board's Audit, Remuneration and Nomination Committees.
From 15 March 2018, the composition of the Board of Oxford
BioMedica is as follows:
-- Dr. Lorenzo Tallarigo, Non-Executive Chairman
-- John Dawson, Chief Executive Officer
-- Stuart Paynter, Chief Financial Officer
-- Peter Nolan, Chief Business Officer
-- Andrew Heath, Independent Non-Executive Director
-- Stuart Henderson, Independent Non-Executive Director
-- Martin Diggle, Non-Executive Director
-- Heather Preston, Independent Non-Executive Director
There are no further details in respect of Dr. Heather Preston
to be disclosed pursuant to LR 9.6.13 of the Listing Rules, FCA
Handbook.
- Ends -
For further information,
please contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive 783 000
Officer
Stuart Paynter, Chief Financial
Officer
Financial and corporate communications Tel: +44 (0)20 3709
enquiries: 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew
Neal/Philippa Gardner/Laura
Thornton
Peel Hunt (Joint Corporate Tel: +44 (0)20 7418
Brokers): 8900
James Steel
Christopher Golden
WG Partners (Joint Corporate Tel: +44 (0)20 3705
Brokers): 9321
David Wilson
Claes Spang
The information contained within this announcement is deemed by
the Group to constitute inside information as stipulated under the
Market Abuse Regulation (EU) No. 596/2014. Upon the publication of
this announcement via the Regulatory Information Service, this
inside information is now considered to be in the public
domain.
Notes for editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
group focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ), which the Group leverages to develop in vivo and
ex vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Bioverativ, Novartis, Sanofi, GSK,
Orchard Therapeutics and Immune Design, through which it has
long-term economic interests in other potential gene and cell
therapy products. Oxford BioMedica is based across several
locations in Oxfordshire, UK and employs more than 300 people.
Further information is available at www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAFKPDPABKKNND
(END) Dow Jones Newswires
March 15, 2018 03:02 ET (07:02 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024